KUALA LUMPUR, Jan 23 -- Ferring Pharmaceuticals announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare in Japan.
Propess is a vaginal delivery system containing the active substance dinoprostone 10mg used for the initiation of cervical ripening in women at term (from 37 completed weeks of gestation).
The dinoprostone softens and opens the part of the birth canal known as the cervix, to start the process of labour.
According to a statement, this is the first time in over 20 years that a pharmacological therapy for cervical ripening has been approved in the country.
This approval offers women requiring an induction in Japan greater choice of alternatives to mechanical methods of cervical ripening.
Ferring Pharmaceuticals president and chief science officer, Per Falk said: “There is a lack of research and development of treatment options for women who are pregnant or giving birth, which is why it is important for Ferring to continue to invest and advance the field of Reproductive Medicine and Maternal Health and continue with our purpose of building families worldwide.”
The announcement follows close collaboration between Ferring Pharmaceuticals and a local patient advocacy group to ensure the needs and safety of women in labour are addressed in Japan.
Propess is currently marketed in over 60 countries and was developed in the 1980s in Scotland where it continues to be manufactured. More details at https://www.ferring.com/
-- BERNAMA
No comments:
Post a Comment